This content is machine translated Tofacitinib for ulcerative colitis Study shows real-world evidence for efficacy and safety The prevalence of ulcerative colitis (CU) in Switzerland is 1/500. The JAK inhibitor tofacitinib has been an arrow in the treatment quiver since 2019. In the phase 3 OCTAVE study,…
View Post 6 min This content is machine translated Light chain amyloidosis New echocardiographic risk score? The prognosis of light chain amyloidosis (AL), a plasma cell dyscrasia, is largely determined by the presence of cardiac involvement. Conventional staging is based on cardiac biomarkers and free light…
